About

The Cancer News (TCN), Binaytara Foundation’s news media, is an authoritative resource featuring independent and expert analysis in the field of hematology and oncology. Our target audience is hematology, oncology professionals, and others interested in cancer care. Our goal is to improve patient outcomes.

Our Mission

At The Cancer News, we dissect the latest research and complex cancer information and disseminate knowledge to oncology professionals and others interested in cancer care. We aim to improve patient-centered care and outcomes.

editorial Board Members

Editor-in-chief

Dipesh Uprety, MBBS, FACP

Barbara Ann Karmanos Cancer Institute, MI, USA

Managing Editor

Saramshika Dhakal, MBBS

Tribhuvan University Teaching Hospital, Kathmandu, Nepal

Chepsy Philip, MD

Believers Church Medical College Hospital, Kerala, India

Anish Shah, MD

BronxCare Health System, NY, USA

Kanak Parmar, MD

Texas Tech University Health Sciences Center, TX, USA

Richa Parikh, MD

Barbara Ann Karmanos Cancer Institute, MI, USA

Aditi Sharma, MD

Barbara Ann Karmanos Cancer Institute, MI, USA

Radhika Kulkarni, MD

Henry Ford Cancer Institute, MI, USA

Harsh Parmar, MD

Hackensack University Medical Center, NJ, USA

Abhishek A. Mangaonkar, MBBS

Mayo Clinic, Rochester, MN, USA

Jose Larios, MD

Ascension Providence Hospital, MI, USA

Luke Fletcher, MD

Willamette Valley Cancer Institute and Research Center, OR, USA

Shipra Gandhi, MD

Assistant Professor, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Inas Abuali, MD, FACP

Massachussetts General Hospital Boston, MA

Lei Deng, MD

PGY-6 Fellow of Hematology/Oncology,
Roswell Park Comprehensive Cancer Center, Buffalo, NY

Arya Roy, MD

Roswell Park Comprehensive Cancer Center, Buffalo, NY

Interested in becoming an editor?

We welcome oncologists to join our editorial board. If you are interested in joining or wish to contribute, we would love to hear from you. Please send us a letter of interest and a CV.

Submission Form

→ Click here to view our Editorial Board Member page.

About

Our Mission

editorial Board Members

Editor-in-chief

Dipesh Uprety, MBBS, FACP

Managing Editor

Saramshika Dhakal, MBBS

Chepsy Philip, MD

Anish Shah, MD

Kanak Parmar, MD

Richa Parikh, MD

Aditi Sharma, MD

Radhika Kulkarni, MD

Harsh Parmar, MD

Abhishek A. Mangaonkar, MBBS

Jose Larios, MD

Luke Fletcher, MD

Shipra Gandhi, MD

Inas Abuali, MD, FACP

Lei Deng, MD

Arya Roy, MD

Interested in becoming an editor?

FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes

KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma

Overview of KEYNOTE-671 & NADIM II

Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

Suggestions

About

Our Mission

editorial Board Members

Editor-in-chief

Dipesh Uprety, MBBS, FACP

Managing Editor

Saramshika Dhakal, MBBS

Chepsy Philip, MD

Anish Shah, MD

Kanak Parmar, MD

Richa Parikh, MD

Aditi Sharma, MD

Radhika Kulkarni, MD

Harsh Parmar, MD

Abhishek A. Mangaonkar, MBBS

Jose Larios, MD

Luke Fletcher, MD

Shipra Gandhi, MD

Inas Abuali, MD, FACP

Lei Deng, MD

Arya Roy, MD

Interested in becoming an editor?

FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes

KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma

Overview of KEYNOTE-671 & NADIM II

Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse